SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...

Co-Diagnostics, Inc. announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City, where it will connect with institutional investors and showcase ...

SALT LAKE CITY, Jan. 30, 2025 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of ...

Co-Diagnostics (NASDAQ:CODX) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Co-Diagnostics to ...

The average one-year price target for Co-Diagnostics (NasdaqCM:CODX) has been revised to $38.25 / share. This is an increase of 2,900.00% from the prior estimate of $1.28 dated December 18, 2025. The ...

SALT LAKE CITY, Sept. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of ...

SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of ...

SALT LAKE CITY, Jan. 7, 2025 /PRNewswire/ -- Co-Diagnostics (CODX), Inc. (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular ...

SALT LAKE CITY, June 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, ...